 In addition to the CFU and TTP related primary and secondary outcome measures, other outcomes measures such as the pharmacokinetics of faropenem, change in RPF-dependent colony counts, change of expression of select signature Mtb genes in sputum transcriptome, changes in host transcriptome and change in host immune profile will be determined. 